BRPI0413215A - peptìdeos com capacidade de ligar-se a um fator de crescimento transformador beta 1(tgf-beta) - Google Patents

peptìdeos com capacidade de ligar-se a um fator de crescimento transformador beta 1(tgf-beta)

Info

Publication number
BRPI0413215A
BRPI0413215A BRPI0413215-7A BRPI0413215A BRPI0413215A BR PI0413215 A BRPI0413215 A BR PI0413215A BR PI0413215 A BRPI0413215 A BR PI0413215A BR PI0413215 A BRPI0413215 A BR PI0413215A
Authority
BR
Brazil
Prior art keywords
tgf
beta
growth factor
transforming growth
binding
Prior art date
Application number
BRPI0413215-7A
Other languages
English (en)
Inventor
Javier Dotor Herrerias
Ana Belen Lopez Vazquez
Juan Jose Lasarte Sagastibelza
Prieto Valtue A Jesus
Francisco Borras Cuesta
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of BRPI0413215A publication Critical patent/BRPI0413215A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PEPTìDEOS COM A CAPACIDADE PARA LIGAREM-SE A FATOR DE CRESCIMENTO TRANSFORMADOR BETA 1 (TGF-BETA 1) Os peptídeos descritos possuem a capacidade para ligarem-se a Fator de Crescimento Transformador TGF-beta 1 (TGF-beta1), e são potenciais inibidores da atividades biológica de TGF-beta 1 através da ligação direta a esta citoquina. Estes peptídeos podem ser usados no tratamento de doenças ou alterações patológicas baseadas na expressão TGF-beta 1 desregulada ou excessiva.
BRPI0413215-7A 2003-08-22 2004-07-05 peptìdeos com capacidade de ligar-se a um fator de crescimento transformador beta 1(tgf-beta) BRPI0413215A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302020A ES2304069B1 (es) 2003-08-22 2003-08-22 Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
PCT/ES2004/000320 WO2005019244A1 (es) 2003-08-22 2004-07-05 Péptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-beta1)

Publications (1)

Publication Number Publication Date
BRPI0413215A true BRPI0413215A (pt) 2007-06-19

Family

ID=34203356

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413215-7A BRPI0413215A (pt) 2003-08-22 2004-07-05 peptìdeos com capacidade de ligar-se a um fator de crescimento transformador beta 1(tgf-beta)

Country Status (18)

Country Link
US (1) US7666841B2 (pt)
EP (1) EP1669367B1 (pt)
JP (1) JP4902352B2 (pt)
CN (1) CN100424093C (pt)
AT (1) ATE479702T1 (pt)
AU (2) AU2004266856A1 (pt)
BR (1) BRPI0413215A (pt)
CA (1) CA2535807A1 (pt)
CY (1) CY1110885T1 (pt)
DE (1) DE602004028949D1 (pt)
DK (1) DK1669367T3 (pt)
ES (2) ES2304069B1 (pt)
HR (1) HRP20100637T1 (pt)
PL (1) PL1669367T3 (pt)
PT (1) PT1669367E (pt)
RU (2) RU2333917C2 (pt)
SI (1) SI1669367T1 (pt)
WO (1) WO2005019244A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
EP1974740A4 (en) * 2005-10-24 2010-09-01 Proyecto Biomedicina Cima Sl USE OF TGF-BETA1 INHIBITORY PEPTIDES IN THE PREPARATION OF AN IMMUNE RESPONSE MODULATING AGENT
ES2327088B1 (es) * 2007-08-20 2010-07-26 Proyecto De Biomedicina Cima S.L. Combinaciones terapeuticas para el tratamiento de las metastasis.
ES2337973B8 (es) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
ES2330826B1 (es) 2008-06-04 2010-07-26 Proyecto De Biomedicina Cima, S.L. Sistema para empaquetamiento de adenovirus de alta capacidad.
RU2567667C2 (ru) 2008-06-13 2015-11-10 Проекто Де Биомедисина Сима, С.Л. Конъюгаты для введения биологически активных соединений
CN102307598A (zh) * 2009-02-05 2012-01-04 迪格纳生物技术公司 TGF-β1抑制肽的药物制剂
BR112012010755A2 (pt) 2009-11-05 2015-09-22 Proyecto Biomedicina Cima Sl constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
WO2012001196A2 (es) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos
KR101029705B1 (ko) * 2010-06-30 2011-04-18 (주)엔솔테크 신규 펩타이드 및 그 용도
EP2407534A1 (en) 2010-07-14 2012-01-18 Neo Virnatech, S.L. Methods and reagents for obtaining transcriptionally active virus-like particles and recombinant virions
ES2781866T3 (es) 2011-11-28 2020-09-08 Inst Catalana Recerca Estudis Avancats Métodos y kits para el pronóstico de cáncer colorrectal
WO2013113755A1 (en) 2012-01-30 2013-08-08 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
US20150289795A1 (en) 2012-11-12 2015-10-15 Institució Catalana De Recerca I Estudis Avançats Methods and kits for the prognosis of colorectal cancer
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
WO2015072580A1 (ja) 2013-11-14 2015-05-21 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
EP2878674A1 (en) 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
EP3089755A1 (en) 2014-01-03 2016-11-09 Fundacion Biofisica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
US20170121685A1 (en) 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
WO2017110093A1 (ja) 2015-12-24 2017-06-29 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
CA3070938A1 (en) 2017-07-26 2019-01-31 The Doshisha Drug for treating or preventing disorder caused by tgf-.beta. signalling, and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
CN1826137A (zh) * 2002-11-01 2006-08-30 博伊斯镇国家研究医院 α1β1整联蛋白的可诱导的配体和用途

Also Published As

Publication number Publication date
RU2333917C2 (ru) 2008-09-20
JP4902352B2 (ja) 2012-03-21
ES2304069B1 (es) 2009-08-12
HRP20100637T1 (hr) 2010-12-31
EP1669367B1 (en) 2010-09-01
DK1669367T3 (da) 2010-11-08
CN100424093C (zh) 2008-10-08
US20070142275A1 (en) 2007-06-21
CY1110885T1 (el) 2015-06-10
PT1669367E (pt) 2010-12-07
JP2007525204A (ja) 2007-09-06
ES2304069A1 (es) 2008-09-01
AU2010212466A1 (en) 2010-09-09
CN1839149A (zh) 2006-09-27
ES2351865T3 (es) 2011-02-11
PL1669367T3 (pl) 2011-02-28
DE602004028949D1 (en) 2010-10-14
ATE479702T1 (de) 2010-09-15
RU2455358C2 (ru) 2012-07-10
CA2535807A1 (en) 2005-03-03
AU2010212466B2 (en) 2012-07-19
RU2006109011A (ru) 2006-07-27
US7666841B2 (en) 2010-02-23
RU2008115678A (ru) 2009-10-27
AU2004266856A1 (en) 2005-03-03
SI1669367T1 (sl) 2010-11-30
EP1669367A1 (en) 2006-06-14
WO2005019244A1 (es) 2005-03-03

Similar Documents

Publication Publication Date Title
BRPI0413215A (pt) peptìdeos com capacidade de ligar-se a um fator de crescimento transformador beta 1(tgf-beta)
BR0113420A (pt) Anticorpos para il-1beta humano
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
ATE432072T1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
CY1114443T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
BRPI0411013A (pt) implante para uso na fusão de estruturas ósseas adjacentes, método de tratar um organismo para promover fusão de estruturas ósseas adjacentes e sistema para uso na fusão de estruturas ósseas adjacentes
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE60313021D1 (de) 4-tetrazolyl-4-phenylpiperidindervate zur schmerzbehandlung
EA200601884A1 (ru) Бета-карболины, применяемые для лечения воспалительных заболеваний
DE602004016385D1 (de) Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
TNSN07036A1 (en) Human monoclonal antibodies against human il-4
WO2009067177A3 (en) Bone morphogenic protein binding peptide
ATE417605T1 (de) Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
ATE475315T1 (de) Mittel zur biologischen bekämpfung pilzlicher pflanzenkrankheiten
ATE416756T1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
DE602005019770D1 (de) Medizinische zusammensetzung zur behandlung von krebs oder diabetes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2261 DE 06/05/2014.